Return to: Previous Page

SHAREHOLDER ALERT: Brower Piven Encourages Investors With More Than $75,000 in Losses From Investment in BioScrip, Inc. to Contact Brower Piven Before the November 29, 2013 Lead Plaintiff Deadline10-1-13 5:30 PM EDT

STEVENSON, Md., Oct. 1, 2013 (GLOBE NEWSWIRE) -- Brower Piven, A Professional Corporation announces that a class action lawsuit has been commenced in the United States District Court for the Southern District of New York on behalf of purchasers of BioScrip, Inc. ("BioScrip" or the "Company") (Nasdaq:BIOS) securities during the period between August 8, 2011 and September 20, 2013, inclusive (the "Class Period").

If you have suffered a net loss from investment in BioScrip, Inc. securities purchased on or after August 8, 2011, and held through the revelation of negative information on September 23, 2013, as described below, at no cost to you, you may obtain additional information about this lawsuit and your ability to become a lead plaintiff by contacting Brower Piven at www.browerpiven.com, by email at hoffman@browerpiven.com, by calling 410/415-6616, or at Brower Piven, A Professional Corporation, 1925 Old Valley Road, Stevenson, Maryland 21153. Attorneys at Brower Piven have combined experience litigating securities and class action cases of over 60 years.

No class has yet been certified in the above action.  Members of the Class will be represented by the lead plaintiff and counsel chosen by the lead plaintiff.  If you wish to choose counsel to represent you and the Class, you must apply to be appointed lead plaintiff no later than November 29, 2013 and be selected by the Court.  The lead plaintiff will direct the litigation and participate in important decisions including whether to accept a settlement and how much of a settlement to accept for the Class in the action.  The lead plaintiff will be selected from among applicants claiming the largest loss from investment in the Company during the Class Period.

The complaint accuses the defendants of violations of the Securities Exchange Act of 1934 by virtue of the defendants' failure to disclose during the Class Period that the Company's improper distribution of its product Exjade through its specialty pharmacy operations violated certain federal and/or state laws and/or regulations. According to the complaint, following the Company's September 23, 2013 disclosure that it had received a civil investigative demand issued by the U.S. Attorney's Office for the Southern District of New York and a subpoena from the New York State Attorney General's Medicaid Fraud Control Unit, concerning the distribution of Exjade product by the Company's legacy specialty pharmacy division, the value of BioScrip shares declined significantly.

If you choose to retain counsel, you may retain Brower Piven without financial obligation or cost to you, or you may retain other counsel of your choice.  You need take no action at this time to be a member of the class.

CONTACT: Charles J. Piven
         Brower Piven, A Professional Corporation
         Stevenson, Maryland
         410/415-6616
         hoffman@browerpiven.com
Return to: Previous Page